Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines

Journal of Interferon and Cytokine Research

Volumn 19, Issue 12, 1999, Pages 1391-1401

  El Shami, Khaled M ^a,b   Tzehoval, Esther ^a   Vadai, Ezra ^a   Feldman, Michael ^a   Eisenbach, Lea ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; CYTOTOXICITY TEST; FEMALE; GENETIC TRANSFECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION;

ANIMALS; BASE SEQUENCE; CANCER VACCINES; CELL MEMBRANE; CYTOKINES; DNA PRIMERS; FEMALE; GENE EXPRESSION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERFERON-GAMMA, RECOMBINANT; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 0033427204     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999099312858     Document Type: Article

References (26)

1. DRANOFF, G., JAFFEE, E.M., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., JACKSON, V., HAMADA, H., PARDOLL, D.M., MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific, and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543.
2. GANSBACHER, D., ZIER, K., DANIELS, B., CRONIN, K., BANNERJI, R., GILBOA, E. (1990). Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
3. PORGADOR, A., BANNERJI, R., WATANABE, Y., GILBOA, E., FELDMAN, M., EISENBACH, L. (1993). Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells. J. Immunol. 150, 1458-1470.
4. PORGADOR, A., TZEHOVAL, E., KATZ, A., VADAI, E., REVEL, M., FELDMAN, M., EISENBACH, L. (1992). Interleukin 6 gene transfection into Lewis lung carcinoma cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52, 3679-3686.
5. ZITVOGEL, L., TAHARA, H., ROBBINS, B.D., STORKUS, W.J., CLARKE, M.R., NALESNIK, M.A., LOTZE, M.T. (1995). Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically-engineered fibroblasts. J. Immunol. 155, 1393-1403.
6. PARDOLL, D.M. (1995). Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13, 339-415.
7. BENNERJI, R., ARROYO, C.D., CORDON-CARDO, C., GILBOA, E. (1994). The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J. Immunol. 152, 2324-2332.
8. TEPPER, R.I., COFFMAN, R.L., LEDER, P. (1992). An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257, 548-551.
9. TEPPER, R.I., MULE, J.J. (1994). Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gen Ther. 5, 153-164.
10. DRANOFF, G., MULLIGAN, R.C. (1995). Gene transfer as cancer therapy. Adv. Immunol. 58, 417-454.
11. COLOMBO, M.P., MODESTI, A., PARMIANI, G., FORNI, G. (1992). Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 52, 4853-4860.
12. PORGADOR, A., FELDMAN, M., EISENBACH, E. (1993). Immunotherapy of tumor metastasis via gene therapy. Nat. Immun. 13, 113-130.
13. LOTZE, M.T. (1992). T-cell growth factors and the treatment of patients with cancer. Clin. Immunol. Immunopathol. 62, S47-S54.
14. MULE, J.J., McINTOSH, J.K., JABLONS, D.M., ROSENBERG, S.A. (1992). Antitumor activity of recombinant interleukin-6 in mice. J. Exp. Med. 171, 629-636.
15. PALLADINO, M.A., SHALABY, M.R., KRAMER, S.M., FERRAIOLO, B.L., BAUGHMAN, R.A., BAUGHMAN, R.A., DELEO, A.B., CRASE, D., MARAFINO, B., AGGRAWAL, B.B., FIGARI, I.S., et al. (1987). Characterization of the antitumor ac- tivities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J. Immunol. 138, 4023-4032.
16. KUPFER, A., SWAIN, S.L., JANEWAY, C.A., SINGER, S.J. (1986). The specific direct interaction of helper T cells and antigen-presenting B cells. Proc. Natl. Acad. Sci. USA 83, 6080-6083.
17. b gene. Proc. Natl. Acad. Sci. USA 85, 4463-4467.
18. TAO, M.-H., LEVY, R. (1993). Idiotype/granulocyte-macrophage colony stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362, 755-758.
19. MANDELBOIM, O., VADAI, E., FELDMAN, M., EISENBACH, L. (1995). Expression of two H-2K genes, syngeneic and allogeneic, as a strategy for potentiating immune recognition of tumor cells. Gene Ther. 2, 757-765.
20. YANG, X., HAYGLASS, K. (1993). A simple, sensitive, dual mAb-based ELISA for murine gamma interferon determination: comparison with common bioassays. J. Immunoassay 14, 129-148.
21. PEREZ, C., ALBERT, I., DEFAY, K., ZACHARIADES, N., GOODING, L., KRIEGLER, M. (1990). A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63, 251-258.
22. PIETRAVALLE, F., LECOANET-HENCHOZ, S., AUBRY, J.P., ELSON, G., BONNEFOY, J.Y., GAUCHAT, J.F. (1996). Cleavage of membrane-bound CD40 ligand is not required for inducing B cell proliferation and differentiation. Eur. J. Immunol. 26, 725-728.
23. TANAKA, M., ITAI, T., ADACHI, M., NAGATA, S. (1998). Downregulation of Fas ligand by shedding. Nat. Med. 4, 31-36.
24. FIDLER, I.J. (1990). Critical factors in the biology of human cancer metastasis: twenty-eighth G. H. A. Clowes Memorial Award Lecture. Cancer Res. 50, 6130-6138.
25. MARR, R.A., ADDISON, C.L., SNIDER, D., MULLER, W.J., GAULDIE, J., GRAHAM, F.L. (1997). Tumor immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNFα. Gene Ther. 4, 1181-1188.
26. THOMPSON, R.C., PARDOLL, D.M., JAFFEE, E.M., EWEND, M.G., THOMAS, M.C., TYLER, B.M., BREM, H. (1997). Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J. Immunother. 19, 405-413.